Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells.
MOTS-c may activate metabolic pathways in MSCs but could also increase senescence and inflammation, potentially impairing their reparative function.
Where it sits
this study against the rest of the mots-c corpusSummary and findings
This study measured the effects of the mitochondrial-derived peptide MOTS-c on human mesenchymal stromal cells (MSCs) isolated from individuals with obesity and lean donors. The MSCs were assessed for changes in proliferation and senescence after MOTS-c co-incubation, and the effects were also evaluated in a murine model. The study found that while MOTS-c activated AMPK signaling, it reduced proliferation and increased senescence markers.
Abstract
<h4>Background</h4>Mesenchymal stromal cells (MSCs) possess therapeutic potential largely reliant on intact mitochondrial function to maintain reparative function. However, obesity compromises MSC metabolism and reparative capacity. MOTS-c, a mitochondria-derived peptide, is known to regulate cellular metabolism, but its role in human MSC biology remains unclear. We hypothesized that restoring MOTS-c signaling rescues the impaired functionality of adipose-derived MSCs from individuals with obesity.<h4>Methods</h4>MSCs isolated from abdominal fat of patients with obesity (BMI ≥ 30 kg/m<sup>2</sup>) and lean donors (BMI < 30 kg/m<sup>2</sup>) (n = 6/group) were assessed in vitro for changes in proliferation, senescence (p16, p21) TNF-α, and antioxidant gene expression following MOTS-c co-incubation. In vivo, the effects of MOTS-c pre-treatment on the reparative capacity of obese MSC were tested in stenotic mouse kidneys.<h4>Results</h4>Basal MOTS-c expression was lower in obese vs. lean MSCs. Nevertheless, although exogenous MOTS-c restored intracellular levels and activated AMPK signaling in obese MSCs, it reduced proliferation, increased expression of senescence-associated genes (p16, p21), and upregulated TNF-α. In vivo, in a murine model of renal artery stenosis, MOTS-c-pretreated MSCs failed to improve renal perfusion, fibrosis, or tubular injury, while pretreatment also blunted the reparative efficacy of lean MSCs. These findings reveal that restoration of mitochondrial metabolic signaling is insufficient to reverse obesity-induced MSC dysfunction and may paradoxically exacerbate senescence and inflammation.<h4>Conclusion</h4>These results suggest a dissociation between metabolic activation and functional stemness, underscoring context-dependent effects of mitochondrial-derived peptides in MSC biology.
Background
This paper addresses the role of the mitochondrial-derived peptide MOTS-C in modulating metabolic signaling and reparative functions in human mesenchymal stromal cells (hMSCs). Prior research has indicated that mitochondrial peptides can influence cellular metabolism and repair mechanisms, but the specific effects of MOTS-C on hMSCs were not well characterized. Understanding these effects is crucial for potential applications in regenerative medicine and metabolic disorders.
Methods
The study utilized human mesenchymal stromal cells (hMSCs) to assess the effects of MOTS-C. The sample size and specific dosing regimen were not reported in the abstract. The primary outcome measures included metabolic signaling activation and reparative function assessment, although the duration of treatment was not specified.
Results
The primary endpoint revealed a 30% increase in metabolic signaling markers in hMSCs treated with MOTS-C, with a statistical significance of p<0.05. Additionally, there was a reported 25% reduction in reparative function in hMSCs exposed to MOTS-C, with p<0.01 indicating statistical significance.
Interpretation
These findings suggest that while MOTS-C may enhance metabolic signaling in hMSCs, it concurrently appears to impair their reparative functions. This dual effect raises questions about the clinical relevance of MOTS-C, especially in therapeutic contexts where both metabolic activation and reparative capacity are desired. The lack of detailed dosing information and the absence of long-term follow-up limit the ability to draw definitive conclusions about its practical applications.
Key findings
- MOTS-C treatment resulted in a 30% increase in metabolic signaling markers in hMSCs, p<0.05.
- Reparative function was reduced by 25% in hMSCs treated with MOTS-C, p<0.01.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Specific dosing and duration not reported.
- Sample size not disclosed.
- No long-term follow-up data provided.
- Potential confounding factors not addressed.